Literature DB >> 28523551

Epigenetic Mechanisms of Gene Regulation in Amyotrophic Lateral Sclerosis.

Alba Jimenez-Pacheco1,2, Jaime M Franco1,2, Soledad Lopez1,2, Juan Miguel Gomez-Zumaquero3, Maria Magdalena Leal-Lasarte1, Diana E Caballero-Hernandez1,4, Marta Cejudo-Guillén1,2, David Pozo5,6.   

Abstract

Despite being clinically described 150 years ago, the mechanisms underlying amyotrophic lateral sclerosis (ALS) pathogenesis have not yet been fully understood. Studies in both animal models of ALS and human patients reveal a plethora of alterations such as increased glutamate-mediated excitotoxicity, redox stress, increased apoptosis, defective axonal transport, protein-misfolding events, mitochondrial impairment and sustained unregulated immune responses. Regardless of being sporadic or familiar ALS, the final outcome at the cellular level is the death of upper and lower motor neurons, and once diagnosed, ALS is typically lethal within the next 5 years. There are neither clear biomarkers nor therapeutic or disease-modifying treatments for ALS.Accumulating evidence supports the concept that epigenetic-driven modifications, including altered chromatin remodelling events, RNA editing and non-coding RNA molecules, might shed light into the pathogenic mechanisms underlying sporadic/familiar ALS onset and/or severity to facilitate the identification of effective therapies, early diagnosis and potentially early-stage therapeutic interventions to increase the survival outcome of ALS patients.

Entities:  

Keywords:  Frontotemporal dementia (FTP); Histone acetyl transferases (HAT); Histone deacetylases (HDACs); MicroRNAs; Motor neurone disease (MND); Neurodegeneration; Neurodegeneration, DNA methyltransferases (DNMT); Neuromuscular

Mesh:

Substances:

Year:  2017        PMID: 28523551     DOI: 10.1007/978-3-319-53889-1_14

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  11 in total

1.  Epigenetic Signaling in Glia Controls Presynaptic Homeostatic Plasticity.

Authors:  Tingting Wang; Danielle T Morency; Nathan Harris; Graeme W Davis
Journal:  Neuron       Date:  2019-12-03       Impact factor: 17.173

2.  Liquid biopsy: a new source of candidate biomarkers in amyotrophic lateral sclerosis.

Authors:  Maite Mendioroz; Leyre Martínez-Merino; Idoia Blanco-Luquin; Amaya Urdánoz; Miren Roldán; Ivonne Jericó
Journal:  Ann Clin Transl Neurol       Date:  2018-04-16       Impact factor: 4.511

3.  Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins.

Authors:  Jens Mayer; Christian Harz; Laura Sanchez; Gavin C Pereira; Esther Maldener; Sara R Heras; Lyle W Ostrow; John Ravits; Ranjan Batra; Eckart Meese; Jose Luis García-Pérez; John L Goodier
Journal:  Mol Neurodegener       Date:  2018-08-02       Impact factor: 14.195

Review 4.  Circulating RNAs as Potential Biomarkers in Amyotrophic Lateral Sclerosis.

Authors:  Metka Ravnik-Glavač; Damjan Glavač
Journal:  Int J Mol Sci       Date:  2020-03-03       Impact factor: 5.923

5.  The Novel Regulatory Role of lncRNA-miRNA-mRNA Axis in Amyotrophic Lateral Sclerosis: An Integrated Bioinformatics Analysis.

Authors:  Dingsheng Liu; Xiaojia Zuo; Peng Zhang; Rui Zhao; Donglin Lai; Kaijie Chen; Yuru Han; Guoqing Wan; Yanjun Zheng; Changlian Lu; Xuefeng Gu
Journal:  Comput Math Methods Med       Date:  2021-04-15       Impact factor: 2.238

Review 6.  Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis.

Authors:  Johannes Dorst; Albert C Ludolph; Annemarie Huebers
Journal:  Ther Adv Neurol Disord       Date:  2017-10-09       Impact factor: 6.570

7.  Minimotifs dysfunction is pervasive in neurodegenerative disorders.

Authors:  Surbhi Sharma; Richard J Young; Jingchun Chen; Xiangning Chen; Edwin C Oh; Martin R Schiller
Journal:  Alzheimers Dement (N Y)       Date:  2018-07-25

Review 8.  From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline.

Authors:  Rajka Maria Liscic; Antonella Alberici; Nigel John Cairns; Maurizio Romano; Emanuele Buratti
Journal:  Mol Neurodegener       Date:  2020-06-01       Impact factor: 14.195

Review 9.  When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer's and Huntington's Disease.

Authors:  Santosh R D'Mello
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

Review 10.  Immune Signaling Kinases in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).

Authors:  Raquel García-García; Laura Martín-Herrero; Laura Blanca-Pariente; Jesús Pérez-Cabello; Cintia Roodveldt
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.